SELLAS Life Sciences (SLS) Share-based Compensation (2010 - 2026)
SELLAS Life Sciences (SLS) reported Share-based Compensation of $798000.0 for Q1 2026, up 58.02% year-over-year from $505000.0 in Q1 2025, and up 78.52% on a QoQ basis from $447000.0 in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Share-based Compensation data on file, last reported at $798000.0 in Q1 2026.
- Quarterly Share-based Compensation rose 58.02% year-over-year to $798000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 41.18% YoY) and the FY2025 annual result came in at $2.0 million, up 25.06% from the prior year.
- Share-based Compensation improved to $798000.0 in Q1 2026 per SLS's latest filing, from $447000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $798000.0 in Q1 2026 and bottomed at $334000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $476000.0 (2024), against an average of $478705.9.
- The widest annual swing landed in 2022, when Share-based Compensation jumped 103.8%; it then tumbled 35.02% in 2024.
- Tracing SLS's Share-based Compensation over 5 years: stood at $446000.0 in 2022, then grew by 11.43% to $497000.0 in 2023, then declined by 24.95% to $373000.0 in 2024, then climbed by 19.84% to $447000.0 in 2025, then jumped by 78.52% to $798000.0 in 2026.
- Per Business Quant, the three latest SLS Share-based Compensation figures stand at $798000.0 (Q1 2026), $447000.0 (Q4 2025), and $503000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.15 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 798,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 798,000.00 |
| Mar 31, 2026 | 798,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Sep 30, 2025 | 503,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Jun 30, 2025 | 501,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Mar 31, 2025 | 505,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Dec 31, 2024 | 373,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Jun 30, 2024 | 334,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Mar 31, 2024 | 476,000.00 |
| Dec 31, 2023 | 497,000.00 |
| Dec 31, 2023 | 497,000.00 |
| Sep 30, 2023 | 543,000.00 |
| Sep 30, 2023 | 543,000.00 |
| Jun 30, 2023 | 514,000.00 |
| Jun 30, 2023 | 514,000.00 |
| Mar 31, 2023 | 540,000.00 |
| Mar 31, 2023 | 540,000.00 |
| Dec 31, 2022 | 446,000.00 |
| Dec 31, 2022 | 446,000.00 |
| Sep 30, 2022 | 455,000.00 |
| Sep 30, 2022 | 455,000.00 |
| Jun 30, 2022 | 450,000.00 |
| Jun 30, 2022 | 450,000.00 |
| Mar 31, 2022 | 375,000.00 |
| Mar 31, 2022 | 375,000.00 |
| Dec 31, 2021 | 288,000.00 |
| Dec 31, 2021 | 288,000.00 |
| Sep 30, 2021 | 275,000.00 |
| Sep 30, 2021 | 275,000.00 |
| Jun 30, 2021 | 264,000.00 |
| Jun 30, 2021 | 264,000.00 |
| Mar 31, 2021 | 184,000.00 |
| Mar 31, 2021 | 184,000.00 |
| Dec 31, 2020 | 141,000.00 |
| Dec 31, 2020 | 141,000.00 |
| Sep 30, 2020 | 146,000.00 |
| Sep 30, 2020 | 146,000.00 |
| Jun 30, 2020 | 146,000.00 |
| Jun 30, 2020 | 146,000.00 |
| Mar 31, 2020 | 145,000.00 |
| Mar 31, 2020 | 145,000.00 |
| Dec 31, 2019 | 147,000.00 |
| Dec 31, 2019 | 147,000.00 |
| Sep 30, 2019 | 115,000.00 |
| Sep 30, 2019 | 115,000.00 |
| Jun 30, 2019 | 126,000.00 |
| Jun 30, 2019 | 126,000.00 |
| Mar 31, 2019 | 185,000.00 |
| Mar 31, 2019 | 185,000.00 |
| Dec 31, 2018 | -855,000.00 |
| Dec 31, 2018 | -855,000.00 |
| Sep 30, 2018 | 1.10 Mn |
| Sep 30, 2018 | 1.10 Mn |
| Jun 30, 2018 | 125,000.00 |
| Jun 30, 2018 | 125,000.00 |
| Mar 31, 2018 | 22,000.00 |
| Mar 31, 2018 | 22,000.00 |
| Dec 31, 2017 | -2.84 Mn |
| Dec 31, 2017 | -2.84 Mn |
| Sep 30, 2017 | 1.27 Mn |
| Sep 30, 2017 | 1.27 Mn |
| Jun 30, 2017 | 1.57 Mn |
| Jun 30, 2017 | 1.57 Mn |
| Mar 31, 2017 | 937,000.00 |
| Mar 31, 2017 | 937,000.00 |
| Dec 31, 2016 | -1.48 Mn |
| Dec 31, 2016 | -1.48 Mn |
| Sep 30, 2016 | 552,000.00 |
| Sep 30, 2016 | 552,000.00 |
| Jun 30, 2016 | 622,000.00 |
| Jun 30, 2016 | 622,000.00 |
| Mar 31, 2016 | 656,000.00 |
| Mar 31, 2016 | 656,000.00 |
| Dec 31, 2015 | 1.93 Mn |
| Dec 31, 2015 | 1.93 Mn |
| Sep 30, 2015 | -759,000.00 |
| Sep 30, 2015 | -759,000.00 |
| Jun 30, 2015 | 388,000.00 |
| Jun 30, 2015 | 388,000.00 |
| Mar 31, 2015 | 371,000.00 |
| Mar 31, 2015 | 371,000.00 |
| Dec 31, 2014 | 788,000.00 |
| Dec 31, 2014 | 788,000.00 |
| Sep 30, 2014 | 742,000.00 |
| Sep 30, 2014 | 742,000.00 |
| Jun 30, 2014 | 1.51 Mn |
| Jun 30, 2014 | 1.51 Mn |
| Mar 31, 2014 | 1.62 Mn |
| Mar 31, 2014 | 1.62 Mn |
| Dec 31, 2013 | 963,000.00 |
| Dec 31, 2013 | 963,000.00 |
| Sep 30, 2013 | 729,000.00 |
| Sep 30, 2013 | 729,000.00 |
| Jun 30, 2013 | 251,000.00 |
| Jun 30, 2013 | 251,000.00 |
| Mar 31, 2013 | 364,000.00 |
| Mar 31, 2013 | 364,000.00 |
| Dec 31, 2012 | 326,000.00 |
| Dec 31, 2012 | 326,000.00 |
| Sep 30, 2012 | 447,000.00 |
| Sep 30, 2012 | 447,000.00 |
| Jun 30, 2012 | -97,000.00 |
| Jun 30, 2012 | -97,000.00 |
| Mar 31, 2012 | 718,000.00 |
| Mar 31, 2012 | 718,000.00 |
| Dec 31, 2011 | 2.98 Mn |
| Dec 31, 2011 | 2.98 Mn |
| Mar 31, 2011 | 23,000.00 |
| Mar 31, 2011 | 23,000.00 |
| Dec 31, 2010 | 910,000.00 |
| Dec 31, 2010 | 910,000.00 |
| Sep 30, 2010 | 833,000.00 |
| Sep 30, 2010 | 833,000.00 |